• Medincell’s partner Teva presented new clinical and real-world data at Psych Congress 2026 in New Orleans.
• Post hoc analyses from a late-stage schizophrenia trial supported durable disease control for Teva’s investigational once-monthly olanzapine injectable.
• FDA action date for olanzapine LAI is expected in Q4 2026; the product remains unapproved.
• Separate real-world evidence suggested UZEDY improved treatment continuity, reduced healthcare use versus some competing long-acting antipsychotics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260920971813) on September 21, 2026, and is solely responsible for the information contained therein.